What was recalled
This page synthesizes the threonine source-form and formulation-balance framework in commercial pet food. Threonine is one of nine essential amino acids for dogs and cats — the body cannot synthesize threonine de novo and must obtain it from dietary protein or supplementation. Threonine is structurally distinctive because it carries a hydroxyl group on its side chain (similar to serine) that serves as the attachment site for O-linked glycosylation in mucins and other secreted glycoproteins. Mucins are the heavily glycosylated proteins that form the protective mucus layer over the intestinal epithelium, respiratory epithelium, and other mucosal surfaces, and mucin structure depends on dense threonine residues in repetitive tandem-repeat domains that bear N-acetylgalactosamine (GalNAc) and downstream glycan chains. Intestinal mucin turnover consumes substantial dietary threonine — estimates from porcine and rodent literature suggest 20-40% of dietary threonine flux is allocated to intestinal mucin synthesis under normal physiologic conditions, with further elevation in inflammatory bowel disease and intestinal injury states.
The threonine source forms in commercial pet food include natural L-threonine from animal-tissue protein (animal protein delivers L-threonine at 3.5-5% of total protein content), natural L-threonine from plant protein (legumes deliver 3-4% threonine per protein content; cereal grains deliver 2.5-3.5%), and supplemental L-threonine (fermentation-derived synthetic monomer, used in many plant-protein-anchored formulations to balance the amino acid profile to AAFCO minimums). L-threonine is white crystalline solid, highly water-soluble, dimensionally stable, and substantially more thermally stable than lysine during extrusion processing (Maillard-reaction loss is approximately 1-5% rather than the 5-20% characteristic of lysine). Pet food brands using fermentation-derived L-threonine supplementation in plant-protein-anchored formulations typically achieve AAFCO threonine minimums adequately, but the available / total ratio is closer to 100% than for lysine because of the lower Maillard reactivity of the threonine side chain.
The structural framework for threonine adequacy in pet food formulation depends on the protein anchor. Named-meat-anchored formulations with chicken, beef, lamb, or fish as the dominant protein source deliver substantial natural L-threonine (3.5-5% of protein content) and typically meet AAFCO minimums without supplemental threonine premix. Plant-protein-anchored formulations based on soybean meal, pea protein concentrate, lentils, or chickpeas have lower natural threonine concentrations per protein content (3-4%) and may require supplemental L-threonine to balance the amino acid profile. Cereal-grain-heavy formulations based on corn, wheat, or rice as a substantial protein contributor have the lowest natural threonine (2.5-3.5% of grain protein content), placing threonine as a second or third limiting amino acid behind lysine and methionine in the typical limiting-amino-acid sequence. The structural lever for plant-protein and grain-heavy formulations is supplemental L-threonine premix; named-meat formulations achieve adequacy without premix.
Why it was recalled
The structural controversy has two main layers. Layer one — AAFCO threonine minimum and mucin synthesis demand: AAFCO threonine minimums are set primarily on the basis of protein-synthesis demand for muscle and visceral protein turnover, with mucin-synthesis demand contributing implicitly. The 2014 AAFCO update reviewed amino acid requirements and adjusted some specifications, with threonine retaining the 0.48% canine and 0.73% feline dry-matter minimums. Recent research in porcine, rodent, and limited canine literature has highlighted the substantial contribution of intestinal mucin turnover to total threonine flux, raising the question whether AAFCO minimums are calibrated for healthy intestinal barrier function under physiologic stress (post-surgical recovery, inflammatory bowel disease, intestinal parasitism, chemotherapy-induced enteropathy) or only for nominal protein synthesis. The structural framework supports investigating whether threonine inclusion above AAFCO minimum produces measurable intestinal-barrier benefit in companion animals with active enteropathy, similar to the established framework in porcine production nutrition.
Layer two — plant-protein-anchored formulations face threonine limitation along with methionine and lysine: when plant protein replaces animal protein in pet food formulation, threonine joins lysine and methionine as the trio of amino acids requiring supplemental balance to meet AAFCO minimums. The cumulative supplementation framework (L-lysine HCl + L-threonine + DL- or L-methionine) plus often L-tryptophan addresses the structural amino acid limitations of grain and legume protein bases. The downstream question is whether AAFCO compliance through supplementation-rebalanced plant-protein formulation delivers equivalent functional protein status to named-meat-anchored formulation, and the answer depends on several factors including ingredient bioavailability, processing effects on specific amino acids (lysine Maillard, methionine racemate utilization in cats), and the implicit mucin-synthesis allocation framework. The pea protein 2018-2024 controversy page covers the broader downstream questions about plant-protein-anchored formulations.
Health risks for your pet
Clinical threonine deficiency in commercial-fed dogs and cats on AAFCO-compliant diets is uncommon at the population level. Disproportionate risk concentrates in puppies and kittens during rapid growth (high threonine demand for both protein synthesis and intestinal mucin development), pets with active inflammatory bowel disease or chronic enteropathy (elevated mucin turnover increases threonine demand above AAFCO calibration baseline), boutique and homemade plant-protein-based diets without certified nutritionist oversight, and post-surgical and chemotherapy-recovery pets with elevated intestinal repair demand. Clinical signs of severe threonine deficiency include growth retardation, poor coat quality, increased intestinal permeability (theoretical mechanism through impaired mucin synthesis), and immune dysfunction. Veterinary diagnosis is typically presumptive rather than direct serum measurement, since threonine concentration is not a routine veterinary assay.
Threonine excess from dietary sources is essentially never seen in commercial pet food; safety margins are wide and the amino acid is well-tolerated. Threonine is also one of the more thermally stable essential amino acids during pet food processing, with low Maillard reactivity and minimal extrusion loss, so the available / total threonine ratio is high (95-99% across processing methods). The available lysine framework that drives the lysine source-form controversy does not apply with the same intensity to threonine.
What to do if you bought affected product
Pet owners can manage threonine adequacy through several practical approaches: (1) for healthy adult pets on AAFCO-compliant commercial diets, threonine adequacy is essentially never a clinical limiting factor; the structural controversy is more relevant for puppies and kittens during rapid growth and for pets with active enteropathy; (2) for puppies and kittens during rapid growth, prefer named-meat-anchored growth formulations over plant-protein-anchored alternatives; animal protein delivers L-threonine at 3.5-5% of protein content versus 3-4% for legume protein and 2.5-3.5% for grain protein; (3) for pets with active inflammatory bowel disease, post-surgical recovery, or chronic enteropathy, work with your veterinarian on diet selection that supports elevated mucin-synthesis demand; veterinary therapeutic diets formulated for intestinal recovery typically include elevated threonine and other amino acids relevant to intestinal repair; (4) for plant-protein-anchored formulations, AAFCO compliance through supplemental L-threonine is standard practice and adequate for routine maintenance; the available / total threonine ratio is preserved through extrusion processing better than the available / total lysine ratio; (5) do not stack over-the-counter L-threonine supplementation on AAFCO-compliant complete-and-balanced diet without veterinary indication; the clinical context for therapeutic threonine supplementation is sufficiently narrow that professional supervision is appropriate.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate threonine source form per our published methodology, since brand-level threonine specification beyond AAFCO minimum compliance is essentially absent. The mucin-synthesis demand framework is structurally interesting but not yet supported by companion-animal controlled-trial evidence at the level required for rubric differentiation. Future rubric extension under consideration: brands publishing threonine specification above AAFCO minimum for growth, performance, and intestinal-recovery positioning would receive scoring credit if accompanied by intestinal-health adjunct framework; veterinary therapeutic diets for inflammatory bowel disease typically include this calibration but consumer-facing brands rarely do. For now, our recommendation: assume AAFCO-compliant commercial diets meet threonine requirements adequately for healthy adult pets; for growth and intestinal-recovery contexts, prefer named-meat-anchored formulations or veterinary therapeutic diets; and treat threonine specification as a brand-customer-service inquiry only when active enteropathy or growth concerns are in scope.